Catalog No.
RVV19904
Species reactivity
Dengue virus 1
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Genome polyprotein, Envelope protein E
Concentration
1.74 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8BE40
Applications
ELISA, FCM
Form
Liquid
Storage buffer
100 mM Pro-Ac, 20 mM Arg, pH 5.0
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
E106#
Serotype-Specific Dengue Virus IgG Assay Using EDIII-Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil., PMID:39620308
Envelope domain III E324, E351, and E380 mutations lever adaptive evolution of DENV-1 genotype I., PMID:39230303
Reactivity of DENV-positive sera against recombinant envelope proteins produced in bacteria and eukaryotic cells., PMID:36192522
Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection., PMID:34696387
Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate., PMID:34475493
Aedes aegypti lachesin protein binds to the domain III of envelop protein of Dengue virus-2 and inhibits viral replication., PMID:32141690
The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study., PMID:30934772
First dengue virus seroprevalence study on Madeira Island after the 2012 outbreak indicates unreported dengue circulation., PMID:30867031
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice., PMID:29976679
Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852
Structural Mimicry of the Dengue Virus Envelope Glycoprotein Revealed by the Crystallographic Study of an Idiotype-Anti-idiotype Fab Complex., PMID:28637753
Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies., PMID:27821688
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies., PMID:27301568
Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand., PMID:27265466
[Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus]., PMID:26951013
Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display., PMID:26339794
Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II., PMID:24768848
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement., PMID:24743696
Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination., PMID:24696467
Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design., PMID:23851440
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection., PMID:23785205
Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application., PMID:23658845
Dengue virus tetra-epitope peptide expressed in lettuce chloroplasts for potential use in dengue diagnosis., PMID:23615743
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope., PMID:23055922
Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli., PMID:22420529
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus., PMID:22139356
[Characterization and secreted expression of dengue virus type I-IV envelope glycoprotein domain III in Pichia pastoris]., PMID:21055023
Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III., PMID:20444995
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1., PMID:20369024
Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III., PMID:19101005
Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein., PMID:15542644
For research use only. Not for human or drug use.
